ArriVent BioPharma, Inc. Common Stock
N/A
USD
N/A
N/A
...
Chart
Financials
Description
AVBP Company Description
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
AVBP Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view AVBP Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of AVBP by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by AVBP's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of AVBP in WallStreetBets Daily Discussion
AVBP News
Recent insights relating to AVBP
CNBC Recommendations
Recent picks made for AVBP stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in AVBP
Corporate Flights
Flights by private jets registered to AVBP
Our Analysis